קונבריזה
Country: Israel
Language: Hebrew
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
BAZEDOXIFENE AS ACETATE 20 MG
Available from:
NEOPHARM LTD
ATC code:
G03XC02
Pharmaceutical form:
COATED TABLETS
Administration route:
PER OS
Manufactured by:
PFIZER IRELAND PHARMACEUTICALS
Therapeutic group:
BAZEDOXIFENE
Therapeutic indications:
CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit
Authorization date:
2013-04-01
